Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025
VolitionRx (NYSE AMERICAN: VNRX) announces two significant poster presentations at ESMO's European Lung Cancer Congress (ELCC) 2025 in Paris. The presentations focus on the company's innovative biomarker technologies:
1. The Nu.Q® H3K27Me3 biomarker, combined with circulating tumor DNA, shows potential to improve prognostic value for overall survival and treatment decision-making in Non Small Cell Lung Cancer (NSCLC).
2. The Nu.Q® H3.1 low-cost immunoassay demonstrates potential for early identification of high-risk cancer subjects.
The presentations, scheduled for March 28, 2025, include studies on early detection of stage I/II NSCLC and H3K27Me3-nucleosome as a prognostic biomarker in NSCLC, with analysis of up to 832 patients at baseline.
VolitionRx (NYSE AMERICAN: VNRX) annuncia due importanti presentazioni di poster al Congresso Europeo sul Cancro del Polmone (ELCC) 2025 a Parigi. Le presentazioni si concentrano sulle innovative tecnologie di biomarcatori dell'azienda:
1. Il biomarcatore Nu.Q® H3K27Me3, combinato con il DNA tumorale circolante, mostra potenziale per migliorare il valore prognostico per la sopravvivenza complessiva e la presa di decisioni terapeutiche nel Cancro Polmonare Non a Piccole Cellule (NSCLC).
2. L'immunoassay a basso costo Nu.Q® H3.1 dimostra potenziale per l'identificazione precoce di soggetti oncologici ad alto rischio.
Le presentazioni, programmate per il 28 marzo 2025, includono studi sulla rilevazione precoce dello stadio I/II del NSCLC e sull'H3K27Me3-nucleosoma come biomarcatore prognostico nel NSCLC, con analisi di fino a 832 pazienti alla baseline.
VolitionRx (NYSE AMERICAN: VNRX) anuncia dos presentaciones de póster significativas en el Congreso Europeo sobre Cáncer de Pulmón (ELCC) 2025 en París. Las presentaciones se centran en las innovadoras tecnologías de biomarcadores de la empresa:
1. El biomarcador Nu.Q® H3K27Me3, combinado con el ADN tumoral circulante, muestra potencial para mejorar el valor pronóstico para la supervivencia general y la toma de decisiones sobre el tratamiento en el Cáncer de Pulmón No Microcítico (NSCLC).
2. El inmunoensayo de bajo costo Nu.Q® H3.1 demuestra potencial para la identificación temprana de sujetos con alto riesgo de cáncer.
Las presentaciones, programadas para el 28 de marzo de 2025, incluyen estudios sobre la detección temprana de NSCLC en estadio I/II y el nucleosoma H3K27Me3 como biomarcador pronóstico en NSCLC, con análisis de hasta 832 pacientes en la línea base.
VolitionRx (NYSE AMERICAN: VNRX)는 2025년 파리에서 열리는 유럽 폐암 학회(ELCC)에서 두 개의 중요한 포스터 발표를 발표합니다. 발표는 회사의 혁신적인 바이오마커 기술에 중점을 두고 있습니다:
1. 순환 종양 DNA와 결합된 Nu.Q® H3K27Me3 바이오마커는 비소세포 폐암(NSCLC)에서 전체 생존율과 치료 결정의 예후 가치를 향상시킬 가능성을 보여줍니다.
2. 저비용 면역 분석법인 Nu.Q® H3.1은 고위험 암 환자의 조기 식별 가능성을 보여줍니다.
2025년 3월 28일로 예정된 발표는 NSCLC의 I/II기 조기 발견 및 NSCLC에서 예후 바이오마커로서 H3K27Me3-뉴클레오솜에 대한 연구를 포함하며, 기준선에서 최대 832명의 환자 분석을 포함합니다.
VolitionRx (NYSE AMERICAN: VNRX) annonce deux présentations de posters significatives lors du Congrès Européen sur le Cancer du Poumon (ELCC) 2025 à Paris. Les présentations portent sur les technologies de biomarqueurs innovantes de l'entreprise :
1. Le biomarqueur Nu.Q® H3K27Me3, associé à l'ADN tumoral circulant, montre un potentiel pour améliorer la valeur pronostique pour la survie globale et la prise de décision thérapeutique dans le cancer du poumon non à petites cellules (NSCLC).
2. L'immunoessai à faible coût Nu.Q® H3.1 démontre un potentiel pour l'identification précoce de sujets cancéreux à haut risque.
Les présentations, prévues pour le 28 mars 2025, incluent des études sur la détection précoce du NSCLC au stade I/II et sur le nucléosome H3K27Me3 en tant que biomarqueur pronostique dans le NSCLC, avec une analyse de jusqu'à 832 patients à la ligne de base.
VolitionRx (NYSE AMERICAN: VNRX) kündigt zwei bedeutende Posterpräsentationen auf dem Europäischen Lungenkrebs-Kongress (ELCC) 2025 in Paris an. Die Präsentationen konzentrieren sich auf die innovativen Biomarker-Technologien des Unternehmens:
1. Der Nu.Q® H3K27Me3-Biomarker, kombiniert mit zirkulierender Tumor-DNA, zeigt Potenzial zur Verbesserung des prognostischen Wertes für das Gesamtüberleben und die Entscheidungsfindung bei der Behandlung von nicht-kleinzelligem Lungenkrebs (NSCLC).
2. Der kostengünstige Immunoassay Nu.Q® H3.1 zeigt Potenzial für die frühe Identifizierung von Hochrisiko-Krebspatienten.
Die Präsentationen, die für den 28. März 2025 geplant sind, beinhalten Studien zur frühen Erkennung von NSCLC im Stadium I/II und H3K27Me3-Nukleosomen als prognostischen Biomarker bei NSCLC, mit Analysen von bis zu 832 Patienten zu Beginn der Studie.
- Development of two promising biomarker technologies for cancer detection and prognosis
- Large-scale clinical validation with 832 patients for H3K27Me3 biomarker
- Potential commercial applications in early cancer detection and treatment decision-making
- Results are interim/preliminary, indicating ongoing research phase
- No specific efficacy or accuracy rates disclosed
- Commercial viability and regulatory approval timeline uncertain
Studies demonstrate how Volition's Nu.Q®H3K27Me3 biomarker, when combined with ctDNA, may improve the prognostic value for overall survival and could help inform treatment decisions in NSCLC; and how Volition's Nu.Q® H3.1, low-cost immunoassay may be utilized for the early identification of subjects at high risk of cancer
ELCC 2025 is taking place in
ELCC 2025 Poster Session Details
Poster Session and Table: #282P
Title: "Early detection of stage I/II NSCLC by immunoassay of crosslinked plasma cell fee nucleosomes"
Presenter: Jake Micallef, PhD, MBA, Volition Chief Scientific Officer
Date and Time: Friday, March 28, 2025, 1:00PM – 1:45PM (CET)
Poster Session and Table: #395P
Title: "H3K27Me3-nucleosome is a strong prognostic biomarker in non-small cell lung cancer (NSCLC): Interim results from the analysis of up to 832 patients at baseline"
Presenter: Marie Piecyk, PhD, Researcher, Center for Innovation in Cancerology of
Date and Time: Friday, March 28, 2025, 1:00PM – 1:45PM (CET)
The poster presentations can be viewed at
#282P
#395P
About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients but also to improve their quality of life.
Volition's research and development activities are centered in
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620
Investor Relations:
Jeremy Feffer, LifeSci Advisors, jfeffer@lifesciadvisors.com +1-212-915-2568
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the timing, completion, success and delivery of data from clinical studies, the timing of publications, , the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, and Volition's success in securing licensing and/or distribution agreements with third parties for its products. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this press release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics™, Capture-PCR™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.
View original content:https://www.prnewswire.com/news-releases/volition-announces-two-poster-presentations-at-esmos-european-lung-cancer-congress-2025-302414232.html
SOURCE VolitionRx Limited
FAQ
What are the two key biomarker technologies presented by VNRX at ELCC 2025?
How many patients were included in VNRX's H3K27Me3-nucleosome biomarker study?
What is the potential clinical application of VNRX's Nu.Q® H3K27Me3 biomarker?
What is the main benefit of VNRX's Nu.Q® H3.1 immunoassay?
